Idorsia Adds Hollywood Sparkle To Sleep Drug Quviviq
Jennifer Aniston To Front Unbranded Insomnia Ad Campaign
The Swiss biotech needs to wait for a scheduling review before it can officially launch the insomnia drug Quviviq but this delay gives Idorsia a few months to prime the US market with educational campaigns.
You may also be interested in...
Keeping Track: Idorsia’s Quviviq Is FDA’s First Novel Approval Of 2022; AbbVie’s Rinvoq Gains Eczema Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The Belgian group’s US launch of Bimzelx could be delayed by up to a year after the FDA hit UCB with a complete response letter which states that "certain pre-approval inspection observations must be resolved” before the drug can get the green light for psoriasis.
Despite the impact of the war in Ukraine and spiralling costs, as well as lower COVID-19-based revenues, the German group is forecasting a healthy financial performance for full-year 2022.